251 related articles for article (PubMed ID: 27631462)
1. Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization.
Guilhaumou R; Marsot A; Dupouey J; Galambrun C; Boulamery A; Coze C; Simon N; André N
Ther Drug Monit; 2016 Oct; 38(5):559-66. PubMed ID: 27631462
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.
Marsot A; Gallais F; Galambrun C; Coze C; Blin O; Andre N; Guilhaumou R
Paediatr Drugs; 2018 Aug; 20(4):375-381. PubMed ID: 29736878
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Norvancomycin in Children With Malignant Hematological Disease.
Wang J; Li SC; Ye Q; Gao LL; Nie YM; Xu H; Wu M; Cao P; Wang Y
J Clin Pharmacol; 2020 Sep; 60(9):1220-1230. PubMed ID: 32488878
[TBL] [Abstract][Full Text] [Related]
5. [Vancomycin: what dosages are needed to achieve efficacy in paediatric hematology/oncology?].
Zegbeh H; Bleyzac N; Berhoune C; Bertrand Y
Arch Pediatr; 2011 Aug; 18(8):850-5. PubMed ID: 21664803
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
7. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Study of Vancomycin in Chinese Pediatric Patients with Hematological Malignancies.
Wang H; Huang L; Wang J; Ni Y; Zhu Z; Gao P; Hu Y; Zhang L; Yang J; Fang L
Pharmacotherapy; 2020 Dec; 40(12):1201-1209. PubMed ID: 33070357
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.
Asbury WH; Darsey EH; Rose WB; Murphy JE; Buffington DE; Capers CC
Ann Pharmacother; 1993 Apr; 27(4):490-6. PubMed ID: 8477127
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy.
Suzuki Y; Tokimatsu I; Morinaga Y; Sato Y; Takano K; Kohno K; Ogata M; Hiramatsu K; Itoh H; Kadota J
Clin Chim Acta; 2015 Feb; 440():183-7. PubMed ID: 25476135
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.
Zhao W; Zhang D; Fakhoury M; Fahd M; Duquesne F; Storme T; Baruchel A; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2014 Jun; 58(6):3191-9. PubMed ID: 24663023
[TBL] [Abstract][Full Text] [Related]
17. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis.
Deng C; Liu T; Zhou T; Lu H; Cheng D; Zhong X; Lu W
Int J Clin Pharmacol Ther; 2013 May; 51(5):407-15. PubMed ID: 23458230
[TBL] [Abstract][Full Text] [Related]
18. A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C.
Lu JJ; Chen M; Lv CL; Zhang R; Lu H; Cheng DH; Tang SY; Liu TT
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):535-546. PubMed ID: 32304024
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
